OXGN Share Price

Open 0.74 Change Price %
High 0.74 1 Day 0.00 0.00
Low 0.70 1 Week 0.00 0.00
Close 0.70 1 Month 0.00 0.00
Volume 169586 1 Year -0.17 -19.54
52 Week High 1.02
52 Week Low 0.49
OXGN Important Levels
Resistance 2 0.74
Resistance 1 0.72
Pivot 0.71
Support 1 0.68
Support 2 0.66
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

OXiGENE, Inc. (NASDAQ: OXGN)

OXGN Technical Analysis 1.5
As on 17th Jun 2016 OXGN Share Price closed @ 0.70 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.87 & Buy for SHORT-TERM with Stoploss of 0.68 we also expect STOCK to react on Following IMPORTANT LEVELS.
OXGN Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
OXGN Other Details
Segment EQ
Market Capital 8300945.50
Sector Healthcare
Industry Biotechnology
Offical website http://www.oxigene.com
OXGN Address
OXGN
701 Gateway Boulevard
Suite 210
South San Francisco, CA 94080
United States
Phone: 650-635-7000
Fax: 650-635-7001
Interactive Technical Analysis Chart OXiGENE, Inc. ( OXGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on OXiGENE, Inc.
OXGN Business Profile
OXiGENE, Inc. is a clinical-stage, biopharmaceutical company developing novel therapeutics primarily to treat cancer. The Company primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, and also are associated with visual impairment in a number of ophthalmological diseases and conditions. The Company�s lead compound, ZYBRESTAT is a reversible tubulin binding agent that works by disrupting the network of abnormal blood vessels, or vasculature, within solid tumors, also referred to as vascular disruption. The Company is pursuing development of OXi4503, a second-generation, dual-mechanism VDA, as a treatment for certain solid tumor types and for the treatment of myeloid leukemias, which also represent orphan indications.